Open AccessPost-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma
Author(s) -
Akira Kawasaki,
Hirokazu Murakami,
Takaaki Chou,
Masaru Matsushita,
Masahiro Kizaki
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0259
Subject(s) - carfilzomib , medicine , adverse effect , multiple myeloma , refractory (planetary science) , oncology , intensive care medicine , gastroenterology , bortezomib , physics , astrobiology
Aim: To evaluate the safety and effectiveness of carfilzomib in a real-world setting. Methods: A post-marketing surveillance of Japanese patients with relapsed or refractory multiple myeloma who received carfilzomib treatment was performed. Results: Overall incidences of adverse events of any grade, ≥grade 3 treatment-related adverse events and serious adverse events were 63.5, 44.6 and 37.7% of patients, respectively. No new safety findings were observed. Treatment-related adverse events of special interest (≥5%) were hematological toxicities, infectious disease, cardiac disorders (including cardiac failure, myocardial infarction and QT prolongation), renal disorders, liver failure or liver dysfunction, and hypertension or hypertensive crisis. The overall response rate was 46.5%. Conclusion: Carfilzomib was found to be a safe and effective treatment for relapsed or refractory multiple myeloma in Japanese patients.